NCT07411365 · NOT YET RECRUITING

Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI

This trial tests whether a home-based dual-task training program — pedaling a stationary bike while simultaneously doing digital cognitive exercises on a tablet — can protect everyday functioning and thinking skills in people who have both Parkinson's disease and mild cognitive impairment. It is a Phase NA randomized controlled trial, meaning it is a structured behavioral study comparing two exercise approaches rather than testing a drug, and results are not yet established.

You may qualify if

  • PD diagnosis confirmed by a neurologist
  • PD diagnosis at least for one year
  • Age between 51-80 years
  • German as their mother tongue
  • Diagnosis of PD-MCI according to the Level II criteria of the Movement Disorder Society
  • Cognitive ADL impairment as defined by the FAQ quotient
  • An informant who has given consent to provide information about the participant's activities of daily living (ADLs) and who lives in the participant's home.
  • Access to a WIFI Network at home
  • Unimpaired or corrected vision and hearing
  • Appropriate text comprehension and reading ability
  • Ability to communicate well with the investigator, to understand and comply with the requirements of the study
  • Provide written informed consent to participate in the study and understand the right to withdraw consent at any time without prejudice to future medical care

You're excluded if

  • Diagnosis of PDD
  • Intake of anti-dementia drugs
  • Deep brain stimulation
  • History of brain disease other than PD (e.g. head trauma, stroke, encephalitis) also including muscular diseases (e.g. myestenia gravis or myopathy)
  • Pre-existing condition that limits limb movement (e.g. muscular injuries, knee and hip disorders
  • severe cardiovascular diseases with heart failure
  • severe respiratory diseases (e.g. asthma and lung disease)
  • severe other accompanying illnesses with impairment of lung function
  • renal insufficiency
  • acute stage of infectious disease
  • acute stage of cancer
  • other disease with pronounced physical weakness
  • History of brain disease other than PD, e.g., head trauma, stroke, encephalitis
  • Alcohol, medication, or drug dependency or abuse (except for nicotine)
  • Signs of severe depression indicated by either the 15 item version Geriatric Depression Scale (≥ 5 points)
  • Acute psychosis
  • Any disability or issues that may prevent the subject from completing the informed consent form or other study requirements
  • Other neurodegenerative disease which renders the subject unable to communicate well with the investigator or to understand and comply with the requirements of the study
  • Participation in any clinical investigation of a new compound or therapy within 4 weeks prior to baseline visit, and any other limitation of participation based on local regulations

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-02-19

View full record on ClinicalTrials.gov

All APOE4 clinical trials